Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2462-2471

  Lin, H M ^a   Castillo, L ^a   Mahon, K L ^a,b   Chiam, K ^a   Lee, B Y ^a   Nguyen, Q ^a,c   Boyer, M J ^b,d,e   Stockler, M R ^b,d,e,f   Pavlakis, N ^b,g   Marx, G ^b,h   Mallesara, G ^c,i   Gurney, H ^b,c,j   Clark, S J ^a,k   Swarbrick, A ^a,k   Daly, R J ^l   Horvath, L G ^a,b,c,d,e  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Pharmacogenomic Research for Individualised Medicine (PRIMe) Consortium   (Australia)

^d Department of Medical Oncology Chris O'Brien Lifehouse ^*  (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Department of Microbiology and Infectious Diseases   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h SYDNEY ADVENTIST HOSPITAL   (Australia)

ⁱ CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^j WESTMEAD HOSPITAL   (Australia)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; MICRORNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; RNA, NEOPLASM; ROC CURVE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84900548218     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.181     Document Type: Article

References (37)

1. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68(15): 6162-6170.
2. Bishr M, Saad F (2013) Overview of the latest treatments for castrationresistant prostate cancer. Nat Rev Urol 10: 522-528.
3. Bonauer A, Dimmeler S (2009) The microRNA-17-92 cluster: Still a miRacle Cell Cycle 8(23): 3866-3873.
4. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H (2011) Circulating miRNAs are correlated with tumor prog ression in prostate cancer. Int J Cancer 128(3): 608-616.
5. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC (2012) Changes in circu lating microRNA levels associated with prostate cancer. Br J Cancer 106: 768-774.
6. Cheng HH Mitchell PS Kroh EM Dowell AE Chery L Siddiqui J Nelson PS Vessella RL Knudsen BS Chinn aiyan AM Pienta KJ Morrissey C Tewari M 2013 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia PLoS One 8 7 e69239.
7. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011) MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8): 467-477.
8. Feng B, Wang R, Song HZ, Chen LB (2012) MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 118(13): 3365-3376.
9. Fontana L, Pelosi E, Grec o P, Racanicchi S, Testa U, Liuzzi F, Croce CM, Brunetti E, Grignani F, Peschle C (2007) MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 9(7): 775-787.
10. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G (2012) miR221/222 in cancer: Their role in tumor progression and response to therapy. Curr Mol Med 12(1): 27-33 .
11. Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC (2011) Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determin ing treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9(1): 39-45.
12. Gregory PA, Bracken CP, Bert AG, Goodall GJ (2008) MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7(20): 3112-3118.
13. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7): 1232-1237.
14. Horvath LG, Chatfield MD, Lee-Ng M, Lin H-M, Castillo L, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Wykes R, Henshall SM, Mahon KL (2013) The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 31(Suppl): Abstr e22175.
15. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17(9): 1101-1108.
16. Krichevsky AM, Gabriely G (2009) miR-21: A small multi-faceted RNA. J Cell Mol Med 13(1): 39-53.
17. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP (2011) MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2(2): 171-185.
18. Lee BY, Hochgrafe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG, Daly RJ (2014) Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel res istance in castrate-resistant prostate cancer. Mol Cancer Ther 13(1): 190-201.
19. Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482(7385): 347-355.
20. Mahon KL, Henshall SM, Sutherland RL, Horvath LG (2011) Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 18: R103-R123.
21. Mercatelli N, Coppola V, Bonci D, Mie le F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafre SA (2008) The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate ca rcinoma xenografts in mice. PLoS One 3(12): E4029.
22. Meyer SU, Pfaffl MW, Ulbrich SE (2010) Normalization strategies for microRNA profiling experiments: A ?normal?way to a hidden layer of complexity Biotech nol Lett 32(12): 1777-1788.
23. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O?Briant KC, Allen A, Lin DW, Urban N, Dresche r CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30): 10513-10518.
24. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW (2012) Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localize d prostate cancer. Prostate 73: 346-354.
25. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Ragh avan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520.
26. Poliseno L, Tuccoli A, Mari ani L, Evangelista M, Citti L,Woods K, Mercatanti A, Hammond S, Rainaldi G (2006) MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108(9): 3068-3071.
27. Puhr M Hoefer J Schafer G Erb HH Jung OhS Klocker H Heidegger I Neuwirt H Culig Z 2012 Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 Am J Pathol 181 6 2188-2201.
28. Qi R, Weiland M, Gao X-H, Zhou L, Mi Q-S (2012) Identification of endogenous normalizers for serum MicroRNAs by microarray profiling: U6 small nuclear RNA is not a r eliable normalizer. Hepatology 55(5): 1640-1642.
29. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE (2009) miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69(18): 7165-7169.
30. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J (2003) TM4: A free, open-source system for mi croarray data management and analysis. Biotechniques 34(2): 374-378.
31. Schaefer A, Jung M, Mol lenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126(5): 116 6-1176.
32. Shree T, OlsonOC, Elie BT,Kester JC, GarfallAL, SimpsonK, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Gen es Dev 25(23): 2465-2479.
33. Sita-Lumsden A, Dart DA, Waxman J, Bevan CL (2013) Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 108: 1925-1930.
34. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednison e for advanced prostate cancer. N Engl J Med 351(15): 1502-1512.
35. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS One 7(7): E41561.
36. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW (2011) Serum miRNA-21: Elevated levels in patients with metastatic hormone-refra ctory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71(3): 326-331.
37. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer M J, Stockler MR, KaplanW, Breit SN, Sutherland RL, Henshall SM, Horvath LG (2009) Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 69(19): 7696-7703.